{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:28:05Z","timestamp":1770895685351,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-026-01489-8","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:45:21Z","timestamp":1770893121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone Adverse Events in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy: A Comprehensive Review of the Literature from the Clinical Action Group of the European Calcified Tissue Society"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-2058","authenticated-orcid":false,"given":"Stella","family":"D\u2019Oronzo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anda Mihaela","family":"Naciu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria P.","family":"Yavropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Paccou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Rolvien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem F.","family":"Lems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"1","key":"1489_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/clinpract13010003","volume":"13","author":"AM Basudan","year":"2022","unstructured":"Basudan AM (2022) The role of immune checkpoint inhibitors in cancer therapy. Clin Pract 13(1):22\u201340. https:\/\/doi.org\/10.3390\/clinpract13010003","journal-title":"Clin Pract"},{"key":"1489_CR2","doi-asserted-by":"publisher","first-page":"204201882311571","DOI":"10.1177\/20420188231157194","volume":"14","author":"J Tang","year":"2023","unstructured":"Tang J (2023) Immune checkpoint inhibitors: friend or foe for osteoporosis. Ther Adv Endocrinol Metab 14:20420188231157194. https:\/\/doi.org\/10.1177\/20420188231157194","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1489_CR3","doi-asserted-by":"publisher","unstructured":"Elsayed M, Ye C (2024) Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors? J Immunother Cancer 12(7). https:\/\/doi.org\/10.1136\/jitc-2024-009309","DOI":"10.1136\/jitc-2024-009309"},{"issue":"6","key":"1489_CR4","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, Higham CE et al (2022) Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol 187(6):G1\u2013G21. https:\/\/doi.org\/10.1530\/EJE-22-0689","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1489_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/ijc.33592","volume":"149","author":"DM Filippini","year":"2021","unstructured":"Filippini DM, Gatti M, Di Martino V, Cavalieri S, Fusaroli M, Ardizzoni A, Raschi E et al (2021) Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: case series and large-scale pharmacovigilance analysis. Int J Cancer 149(3):675\u2013683. https:\/\/doi.org\/10.1002\/ijc.33592","journal-title":"Int J Cancer"},{"issue":"1","key":"1489_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","volume":"7","author":"B Trinh","year":"2019","unstructured":"Trinh B, Sanchez GO, Herzig P, Laubli H (2019) Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint Blockade for melanoma. J Immunother Cancer 7(1):52. https:\/\/doi.org\/10.1186\/s40425-019-0528-x","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1489_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40425-018-0417-8","volume":"6","author":"KF Moseley","year":"2018","unstructured":"Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, Lipson EJ et al (2018) Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. J Immunother Cancer 6(1):104. https:\/\/doi.org\/10.1186\/s40425-018-0417-8","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1489_CR8","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/acr.23177","volume":"69","author":"LC Cappelli","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Bingham CO III, Shah AA (2017) Rheumatic and musculoskeletal immune-Related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken) 69(11):1751\u20131763. https:\/\/doi.org\/10.1002\/acr.23177","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1489_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","volume":"7","author":"L Landi","year":"2019","unstructured":"Landi L, D\u2019Inca F, Gelibter A, Chiari R, Grossi F, Delmonte A, Passaro A et al (2019) Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer 7(1):316. https:\/\/doi.org\/10.1186\/s40425-019-0793-8","journal-title":"J Immunother Cancer"},{"key":"1489_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.lungcan.2022.03.006","volume":"166","author":"YJ Zhu","year":"2022","unstructured":"Zhu YJ, Chang XS, Zhou R, Chen YD, Ma HC, Xiao ZZ, Qu X et al (2022) Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays cold immune characteristics in Non-small cell lung cancer. Lung Cancer 166:189\u2013196. https:\/\/doi.org\/10.1016\/j.lungcan.2022.03.006","journal-title":"Lung Cancer"},{"key":"1489_CR11","doi-asserted-by":"publisher","first-page":"100505","DOI":"10.1016\/j.jbo.2023.100505","volume":"43","author":"GJ Joseph","year":"2023","unstructured":"Joseph GJ, Johnson DB, Johnson RW (2023) Immune checkpoint inhibitors in bone metastasis: clinical challenges, toxicities, and mechanisms. J Bone Oncol 43:100505. https:\/\/doi.org\/10.1016\/j.jbo.2023.100505","journal-title":"J Bone Oncol"},{"issue":"9","key":"1489_CR12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ctrv.2015.09.003","volume":"41","author":"S D\u2019Oronzo","year":"2015","unstructured":"D\u2019Oronzo S, Stucci S, Tucci M, Silvestris F (2015) Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev 41(9):798\u2013808. https:\/\/doi.org\/10.1016\/j.ctrv.2015.09.003","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1489_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/nrrheum.2017.213","volume":"14","author":"MC Walsh","year":"2018","unstructured":"Walsh MC, Takegahara N, Kim H, Choi Y (2018) Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity. Nat Rev Rheumatol 14(3):146\u2013156. https:\/\/doi.org\/10.1038\/nrrheum.2017.213","journal-title":"Nat Rev Rheumatol"},{"key":"1489_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cyto.2017.05.024","volume":"97","author":"A Showalter","year":"2017","unstructured":"Showalter A, Limaye A, Oyer JL, Igarashi R, Kittipatarin C, Copik AJ, Khaled AR (2017) Cytokines in Immunogenic cell death: applications for cancer immunotherapy. Cytokine 97:123\u2013132. https:\/\/doi.org\/10.1016\/j.cyto.2017.05.024","journal-title":"Cytokine"},{"key":"1489_CR15","doi-asserted-by":"publisher","first-page":"988365","DOI":"10.3389\/fimmu.2023.988365","volume":"14","author":"VC Brom","year":"2023","unstructured":"Brom VC, Strauss AC, Sieberath A, Salber J, Burger C, Wirtz DC, Schildberg FA (2023) Agonistic and antagonistic targeting of immune checkpoint molecules differentially regulate osteoclastogenesis. Front Immunol 14:988365. https:\/\/doi.org\/10.3389\/fimmu.2023.988365","journal-title":"Front Immunol"},{"issue":"7","key":"1489_CR16","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1172\/JCI133334","volume":"130","author":"K Wang","year":"2020","unstructured":"Wang K, Gu Y, Liao Y, Bang S, Donnelly CR, Chen O, Tao X et al (2020) PD-1 Blockade inhibits osteoclast formation and murine bone cancer pain. J Clin Invest 130(7):3603\u20133620. https:\/\/doi.org\/10.1172\/JCI133334","journal-title":"J Clin Invest"},{"issue":"5","key":"1489_CR17","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bone.2004.06.018","volume":"35","author":"K Nagahama","year":"2004","unstructured":"Nagahama K, Aoki K, Nonaka K, Saito H, Takahashi M, Varghese BJ, Shimokawa H et al (2004) The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Bone 35(5):1059\u20131068. https:\/\/doi.org\/10.1016\/j.bone.2004.06.018","journal-title":"Bone"},{"key":"1489_CR18","doi-asserted-by":"publisher","first-page":"773946","DOI":"10.3389\/fimmu.2022.773946","volume":"13","author":"SR Greisen","year":"2022","unstructured":"Greisen SR, Kragstrup TW, Thomsen JS, H\u00f8rslev-Pedersen K, Hetland ML, Stengaard-Pedersen K, \u00d8stergaard M et al (2022) The programmed death-1 pathway counter-regulates inflammation-induced osteoclast activity in clinical and experimental settings. Front Immunol 13:773946. https:\/\/doi.org\/10.3389\/fimmu.2022.773946","journal-title":"Front Immunol"},{"key":"1489_CR19","doi-asserted-by":"publisher","unstructured":"JosephGJ, Vecchi LA 3rd, Uppuganti S, Kane JF, Durdan M, Hill P, McAdoo G et al (2025) PD-1 blockade regulates skeletal remodeling in a sex- and age-dependent manner. J Bone Min Res 3:zjaf055 https:\/\/doi.org\/10.1093\/jbmr\/zjaf055","DOI":"10.1093\/jbmr\/zjaf055"},{"key":"1489_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejca.2023.03.015","volume":"186","author":"D Lorusso","year":"2023","unstructured":"Lorusso D, Colombo N, Herraez AC, Santin AD, Colomba E, Miller DS, Fujiwara K et al (2023) Health-Related quality of life in patients with advanced endometrial cancer treated with lenvatinib plus pembrolizumab or treatment of physician\u2019s choice. Eur J Cancer 186:172\u2013184","journal-title":"Eur J Cancer"},{"issue":"6","key":"1489_CR21","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1093\/oncolo\/oyac269","volume":"28","author":"R Motzer","year":"2023","unstructured":"Motzer R, George S, Merchan JR, Hutson TE, Song X, Perini RF, Xie R et al (2023) Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab. Oncologist 28(6):501\u2013509. https:\/\/doi.org\/10.1093\/oncolo\/oyac269","journal-title":"Oncologist"},{"issue":"2","key":"1489_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","volume":"23","author":"JD Schoenfeld","year":"2022","unstructured":"Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y et al (2022) Durvalumab plus Tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 23(2):279\u2013291","journal-title":"Lancet Oncol"},{"issue":"3","key":"1489_CR23","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR et al (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19(3):416\u2013426","journal-title":"Lancet Oncol"},{"issue":"1","key":"1489_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","volume":"16","author":"J Mazieres","year":"2021","unstructured":"Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis DL, Barlesi F et al (2021) Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol 16(1):140\u2013150","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1489_CR25","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00198-023-06690-1","volume":"34","author":"C Ye","year":"2023","unstructured":"Ye C, Lee K, Leslie WD, Lin M, Walker J, Kolinsky M (2023) Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event. Osteoporos Int 34(4):735\u2013740. https:\/\/doi.org\/10.1007\/s00198-023-06690-1","journal-title":"Osteoporos Int"},{"issue":"2","key":"1489_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1078-0432.CCR-23-2124","volume":"30","author":"TH Patel","year":"2024","unstructured":"Patel TH, Brewer JR, Fan J, Cheng J, Shen YL, Xiang Y, Zhao H et al (2024) FDA approval summary: Tremelimumab in combination with durvalumab for the treatment of patients with unresectable hepatocellular carcinoma. Clin Cancer Res 30(2):269\u2013273. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-2124","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1489_CR27","doi-asserted-by":"publisher","first-page":"e1599","DOI":"10.1002\/onco.13883","volume":"26","author":"V Makker","year":"2021","unstructured":"Makker V, Taylor MH, Oaknin A, Casado Herraez A, Orlowski R, Dutta L, Ren M et al (2021) Characterization and management of adverse reactions in patients with advanced endometrial carcinoma treated with lenvatinib plus pembrolizumab. Oncologist 26(9):e1599\u2013e1608. https:\/\/doi.org\/10.1002\/onco.13883","journal-title":"Oncologist"},{"key":"1489_CR28","doi-asserted-by":"publisher","unstructured":"Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T, Hironaka S et al (2017) Y. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol 18(5):631\u2013639. https:\/\/doi.org\/10.1016\/S1470-2045(17)30181-X","DOI":"10.1016\/S1470-2045(17)30181-X"},{"issue":"8","key":"1489_CR29","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1182\/bloodadvances.2022008344","volume":"7","author":"A Younes","year":"2023","unstructured":"Younes A, Burke JM, Cheson BD, Diefenbach CS, Ferrari S, Hahn UH, Hawkes EA et al (2023) Safety and efficacy of Atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma. Blood Adv 7(8):1488\u20131495. https:\/\/doi.org\/10.1182\/bloodadvances.2022008344","journal-title":"Blood Adv"},{"key":"1489_CR30","doi-asserted-by":"publisher","unstructured":"Berton D, Pautier P, Lorusso D, Gennigens C, Gladieff L, Kryzhanivska A, Bowman J et al (2024) Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: final safety and efficacy results from cohort H of the POD1UM-101 phase I study. Gynecol Oncol 186:191\u2013198. https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.025","DOI":"10.1016\/j.ygyno.2024.05.025"},{"key":"1489_CR31","doi-asserted-by":"publisher","first-page":"1199031","DOI":"10.3389\/fphar.2023.1199031","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Li Y, Li J, Zhang Q, Wu J, Li X, Meng L et al (2023) Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study. Front Pharmacol 14:1199031. https:\/\/doi.org\/10.3389\/fphar.2023.1199031","journal-title":"Front Pharmacol"},{"issue":"16","key":"1489_CR32","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","volume":"23","author":"C Weinstock","year":"2017","unstructured":"Weinstock C, Khozin S, Suzman D, Zhang L, Tang S, Wahby S, Goldberg KB et al (2017) U.S. Food and drug administration approval summary: Atezolizumab for metastatic Non-Small cell lung cancer. Clin Cancer Res 23(16):4534\u20134539. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0540","journal-title":"Clin Cancer Res"},{"key":"1489_CR33","doi-asserted-by":"publisher","first-page":"100459","DOI":"10.1016\/j.jbo.2022.100459","volume":"37","author":"F Pantano","year":"2022","unstructured":"Pantano F, Tramontana F, Iuliani M, Leanza G, Simonetti S, Piccoli A, Paviglianiti A et al (2022) Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: an exploratory analysis. J Bone Oncol 37:100459","journal-title":"J Bone Oncol"},{"issue":"5","key":"1489_CR34","doi-asserted-by":"publisher","first-page":"e008669","DOI":"10.1136\/jitc-2023-008669","volume":"12","author":"T Gassner","year":"2024","unstructured":"Gassner T, Chittilappilly C, Pirich T, Neuditschko B, Hackner K, Lind J, Aksoy O et al (2024) Favorable impact of PD1\/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation. J Immunother Cancer 12(5):e008669. https:\/\/doi.org\/10.1136\/jitc-2023-008669","journal-title":"J Immunother Cancer"},{"key":"1489_CR35","doi-asserted-by":"publisher","first-page":"1295923","DOI":"10.3389\/fonc.2023.1295923","volume":"13","author":"EJ Kim","year":"2024","unstructured":"Kim EJ, Kim YJ, Heo JY, Kim M, Lee S, Seo S, Myung J et al (2024) Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study. Front Oncol 13:1295923. https:\/\/doi.org\/10.3389\/fonc.2023.1295923","journal-title":"Front Oncol"},{"key":"1489_CR36","doi-asserted-by":"publisher","first-page":"113604","DOI":"10.1016\/j.ejca.2024.113604","volume":"200","author":"E Ebstein","year":"2024","unstructured":"Ebstein E, Brocard P, Soussi G, Khoury R, Forien M, Khalil A, Vauchier C et al (2024) Burden of comorbidities: osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study. Eur J Cancer 200:113604","journal-title":"Eur J Cancer"},{"key":"1489_CR37","doi-asserted-by":"publisher","first-page":"100642","DOI":"10.1016\/j.jbo.2024.100642","volume":"49","author":"MM Prina","year":"2024","unstructured":"Prina MM, Alberti A, Tovazzi V, Ravanelli M, Schivardi G, Baggi A, Ammoni L et al (2024) Progression of vertebral fractures in metastatic melanoma and non-small cell lung cancer patients given immune checkpoint inhibitors. J Bone Oncol 49:100642","journal-title":"J Bone Oncol"},{"issue":"18","key":"1489_CR38","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1002\/cncr.32206","volume":"125","author":"S Thiruvengadam","year":"2019","unstructured":"Thiruvengadam S, Bauer KE, Bracci PM, Keenan BP, Behr SC, Gordan JD, Kelley RK (2019) Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series. Cancer 125(18):3234\u20133241. https:\/\/doi.org\/10.1002\/cncr.32206","journal-title":"Cancer"},{"issue":"3","key":"1489_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/ph18030333","volume":"18","author":"T Koseki","year":"2025","unstructured":"Koseki T, Hamano H, Hatano M, Tobe T, Ieda R, Nakai T, Zamami Y et al (2025) Fractures associated with immune checkpoint inhibitors: a disproportionality analysis of the world health organization pharmacovigilance database. Pharmaceuticals (Basel) 18(3):333. https:\/\/doi.org\/10.3390\/ph18030333","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"1489_CR40","doi-asserted-by":"publisher","first-page":"e000398","DOI":"10.1136\/bmjonc-2024-000398","volume":"3","author":"C Ye","year":"2024","unstructured":"Ye C, Zhao B, Leslie WD, Ruiz JI, Zhao H, Abdel-Wahab N, Suarez-Almazor ME (2024) Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors. BMJ Oncol 3(1):e000398. https:\/\/doi.org\/10.1136\/bmjonc-2024-000398","journal-title":"BMJ Oncol"},{"key":"1489_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1749-6632.2002.tb04204.x","volume":"966","author":"E Canalis","year":"2002","unstructured":"Canalis E, Delany AM (2002) Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci 966:73\u201381. https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04204.x","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1489_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4049\/jimmunol.1790024","volume":"200","author":"PJ Fink","year":"2018","unstructured":"Fink PJ (2018) The cancer immunotherapy revolution: mechanistic insights. J Immunol 200(2):371\u2013372. https:\/\/doi.org\/10.4049\/jimmunol.1790024","journal-title":"J Immunol"},{"key":"1489_CR43","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","volume":"13","author":"M Conroy","year":"2022","unstructured":"Conroy M, Naidoo J (2022) Immune-related adverse events and the balancing act of immunotherapy. Nat Commun 13:392. https:\/\/doi.org\/10.1038\/s41467-022-27960-2","journal-title":"Nat Commun"},{"key":"1489_CR44","doi-asserted-by":"publisher","first-page":"109290","DOI":"10.1016\/j.ijscr.2024.109290","volume":"115","author":"JK Kang","year":"2024","unstructured":"Kang JK, Lee EH, Lee JN, Kim TH, Kwon TG, Chung JW (2024) Pathologic fractures of the humerus during adjuvant pembrolizumab in patients with renal cell carcinoma after radical nephrectomy: a case report. Int J Surg Case Rep 115:109290. https:\/\/doi.org\/10.1016\/j.ijscr.2024.109290","journal-title":"Int J Surg Case Rep"},{"issue":"9","key":"1489_CR45","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s00198-025-07647-2","volume":"36","author":"V Siampanopoulou","year":"2025","unstructured":"Siampanopoulou V, Ziogas DC, Lyrarakis G, Anastasopoulou A, Kassi E, Gogas H, Angelousi A (2025) Bone mineral density changes following immune checkpoint inhibitor therapy: insights from a case series analysis. Osteoporos Int 36(9):1711\u20131718. https:\/\/doi.org\/10.1007\/s00198-025-07647-2","journal-title":"Osteoporos Int"},{"issue":"1","key":"1489_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.5114\/wo.2021.103829","volume":"25","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A (2021) Epidemiology of lung cancer. Contemp Oncol (Pozn) 25(1):45\u201352. https:\/\/doi.org\/10.5114\/wo.2021.103829","journal-title":"Contemp Oncol (Pozn)"},{"key":"1489_CR47","doi-asserted-by":"publisher","first-page":"1428307","DOI":"10.3389\/fonc.2024.1428307","volume":"14","author":"YH Zheng","year":"2024","unstructured":"Zheng YH, Chen L, Liu X, Li RH, Lei HB, Chen GH (2024) The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis. Front Oncol 14:1428307. https:\/\/doi.org\/10.3389\/fonc.2024.1428307","journal-title":"Front Oncol"},{"key":"1489_CR48","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12943-024-02020-z","volume":"23","author":"L Mont\u00e9gut","year":"2024","unstructured":"Mont\u00e9gut L, L\u00f3pez-Ot\u00edn C, Kroemer G (2024) Aging and cancer. Mol Cancer 23:106. https:\/\/doi.org\/10.1186\/s12943-024-02020-z","journal-title":"Mol Cancer"},{"key":"1489_CR49","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1186\/s13018-021-02821-8","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Darvishi N, Bartina Y, Larti M, Kiaei A, Hemmati M, Shohaimi S et al (2021) Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:669. https:\/\/doi.org\/10.1186\/s13018-021-02821-8","journal-title":"J Orthop Surg Res"},{"issue":"1","key":"1489_CR50","doi-asserted-by":"publisher","first-page":"e000868","DOI":"10.1136\/bmjonc-2025-000868","volume":"4","author":"MP Yavropoulou","year":"2025","unstructured":"Yavropoulou MP, Anastasilakis DA, Kasdagli MI, Gialouri CG, Palaiopanos K, Fountas A, Anastasilakis AD et al (2025) Incidence of fractures in patients with solid cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis of randomised controlled trials. BMJ Oncol 4(1):e000868. https:\/\/doi.org\/10.1136\/bmjonc-2025-000868","journal-title":"BMJ Oncol"},{"issue":"Suppl 2","key":"1489_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3899\/jrheum.2025-0314","volume":"52","author":"M Elsayed","year":"2025","unstructured":"Elsayed M, Greenwood B, Wang X, Dennett L, Ye C (2025) Fracture risk associated with immune checkpoint inhibitors: a systematic literature review and meta-analysis. J Rhuematol 52(Suppl 2):1\u2013124. https:\/\/doi.org\/10.3899\/jrheum.2025-0314 \u00a0(abstract)","journal-title":"J Rhuematol"},{"issue":"3","key":"1489_CR52","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/jbmr\/zjaf009","volume":"40","author":"BE Matheson","year":"2025","unstructured":"Matheson BE, Jaremko JL, Dowhanik A, Gill J, Gallant C, Walker J, Armani N et al (2025) Assessing the effects of immune checkpoint inhibitors on bone utilizing machine learning-assisted opportunistic quantitative computed tomography. J Bone Min Res 40(3):396\u2013403. https:\/\/doi.org\/10.1093\/jbmr\/zjaf009","journal-title":"J Bone Min Res"},{"key":"1489_CR53","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z (2021) PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol 12:731798. https:\/\/doi.org\/10.3389\/fphar.2021.731798","journal-title":"Front Pharmacol"},{"key":"1489_CR54","unstructured":"https:\/\/www.nccn.org\/guidelines\/category_1 Accessed 05 March 2025"},{"issue":"14","key":"1489_CR55","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/1078-0432.CCR-16-0714","volume":"23","author":"JA Beaver","year":"2017","unstructured":"Beaver JA, Theoret MR, Mushti S, He K, Libeg M, Goldberg K, Sridhara R et al (2017) FDA approval of nivolumab for the First-Line treatment of patients with BRAFV600 Wild-Type unresectable or metastatic melanoma. Clin Cancer Res 23(14):3479\u20133483. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0714","journal-title":"Clin Cancer Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01489-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01489-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01489-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:45:24Z","timestamp":1770893124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01489-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01489-8","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no competing interests related to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"26"}}